2025年上半年，国药控股、上海医药、华润医药和九州通四家国内头部药商发布了半年度业绩报告。国药控股以2860.43亿元的营收继续领跑，但其营收同比下降2.95%；上海医药与华润医药分别实现1.56%和0.50%的同比增长，而九州通则以5.10%的增速排名第一。在归母净利润方面，上海医药以44.59亿元居首，同比增长51.56%，但剔除一次性因素后净利润为27.82亿元，同比下降2.06%；九州通...
Source Link2025年上半年，国药控股、上海医药、华润医药和九州通四家国内头部药商发布了半年度业绩报告。国药控股以2860.43亿元的营收继续领跑，但其营收同比下降2.95%；上海医药与华润医药分别实现1.56%和0.50%的同比增长，而九州通则以5.10%的增速排名第一。在归母净利润方面，上海医药以44.59亿元居首，同比增长51.56%，但剔除一次性因素后净利润为27.82亿元，同比下降2.06%；九州通...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.